Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Oramed Pharm ( (ORMP) ) just unveiled an update.
On March 25, 2026, Lifeward Ltd. completed its previously announced acquisition of Oramed’s wholly owned subsidiary Oratech Pharma, Inc., issuing Oramed more than 1.25 million Lifeward ordinary shares, over 1 million pre-funded warrants, and additional warrants to purchase up to 1,296,296 shares, alongside an ongoing 4% revenue share on ReWalk Personal Exoskeleton sales and related warranties, subject to caps and time or valuation triggers. On the same date, Oramed closed a $9 million private placement under which it purchased senior secured convertible notes and accompanying warrants from Lifeward, both initially priced for conversion or exercise at $5.40 per share, deepening Oramed’s equity-linked exposure to Lifeward while monetizing its Oratech asset and securing a continuing stake in Lifeward’s future growth.
The most recent analyst rating on (ORMP) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Oramed Pharm stock, see the ORMP Stock Forecast page.
Spark’s Take on ORMP Stock
According to Spark, TipRanks’ AI Analyst, ORMP is a Neutral.
The score is primarily constrained by weak operating performance and ongoing cash burn despite a solid balance sheet. Offsetting factors include favorable valuation inputs (low P/E and high dividend yield) and positive corporate events that improved liquidity and enabled a dividend, while technical signals are mixed and not strongly directional.
To see Spark’s full report on ORMP stock, click here.
More about Oramed Pharm
Oramed Pharmaceuticals Inc. is a biopharmaceutical company that operates through subsidiaries including Oratech Pharma, Inc., and is focused on transactions involving medical technologies such as Lifeward Ltd.’s ReWalk Personal Exoskeleton products, positioning itself at the intersection of innovative healthcare devices and structured financial investments.
Average Trading Volume: 208,028
Technical Sentiment Signal: Hold
Current Market Cap: $132.7M
For a thorough assessment of ORMP stock, go to TipRanks’ Stock Analysis page.